The Covid-19 vaccine from Pfizer Inc. and partner BioNTech SE was highly effective at reducing the risk of severe disease in children 17 years and younger during the Omicron surge but didn’t work as well at preventing infection, according to a new government study.
The two-dose vaccine reduced the risk of Covid-19 hospitalization in children 5 to 11 years by 74% and by 92% or higher in children 12 to 17, according to the study published Tuesday by the Centers for Disease Control and Prevention.
